Theravance Biopharma, Inc. (TBPH)
Automate Your Wheel Strategy on TBPH
With Tiblio's Option Bot, you can configure your own wheel strategy including TBPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TBPH
- Rev/Share 1.313
- Book/Share 3.3393
- PB 3.3869
- Debt/Equity 0.2901
- CurrentRatio 4.77
- ROIC -0.1798
- MktCap 565514703.0
- FreeCF/Share 0.6495
- PFCF 17.5163
- PE -9.6373
- Debt/Assets 0.1402
- DivYield 0
- ROE -0.3237
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
Read More
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved $225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022 , and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billion First outcome from Strategic Review Committee's ongoing efforts to maximize …
Read More
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Read More
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo.
Read More
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Read More
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.
Read More
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operator Ladies and gentlemen, good afternoon.
Read More
Theravance Biopharma to Participate in an Upcoming Investor Conference
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations.
Read More
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.
Read More
About Theravance Biopharma, Inc. (TBPH)
- IPO Date 2014-05-16
- Website https://www.theravance.com
- Industry Biotechnology
- CEO Rick E. Winningham
- Employees 97